Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARWR Stock Forecast 2025-2026
$41.26
Current Price
$5.70B
Market Cap
Buy 9
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to ARWR Price Targets
+93.9%
To High Target of $80.00
+9.1%
To Median Target of $45.00
-58.8%
To Low Target of $17.00
ARWR Price Momentum
+5.2%
1 Week Change
+5.9%
1 Month Change
+122.2%
1 Year Change
+119.5%
Year-to-Date Change
-5.6%
From 52W High of $43.69
+331.1%
From 52W Low of $9.57
📊 TOP ANALYST CALLS
Did ARWR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Arrowhead is one of their latest high-conviction picks.
Latest ARWR Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, ARWR has a bullish consensus with a median price target of $45.00 (ranging from $17.00 to $80.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $41.26, the median forecast implies a 9.1% upside. This outlook is supported by 9 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 93.9% upside. Conversely, the most conservative target is provided by Shawn Egan at Citigroup, suggesting a 58.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARWR Analyst Ratings
9
Buy
4
Hold
0
Sell
ARWR Price Target Range
Low
$17.00
Average
$45.00
High
$80.00
Current: $41.26
Latest ARWR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARWR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $45.00 |
| Oct 8, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $80.00 |
| Sep 2, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $80.00 |
| Aug 11, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $60.00 |
| Aug 8, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $38.00 |
| May 20, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| May 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $60.00 |
| May 13, 2025 | Citigroup | Shawn Egan | Neutral | Maintains | $17.00 |
| Feb 14, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $38.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Feb 11, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $42.00 |
| Feb 11, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $60.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $80.00 |
| Dec 12, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $60.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $80.00 |
| Nov 29, 2024 | Bernstein | William Pickering | Market Perform | Maintains | $24.00 |
| Nov 27, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $45.00 |
| Nov 27, 2024 | Citigroup | Shawn Egan | Neutral | Maintains | $26.00 |
Arrowhead Pharmaceuticals Inc. (ARWR) Competitors
The following stocks are similar to Arrowhead based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arrowhead Pharmaceuticals Inc. (ARWR) Financial Data
Arrowhead Pharmaceuticals Inc. has a market capitalization of $5.70B with a P/E ratio of -8.3x. The company generates $572.98M in trailing twelve-month revenue with a -25.9% profit margin.
Revenue growth is -94.9% quarter-over-quarter, while maintaining an operating margin of -596.2% and return on equity of -37.1%.
Valuation Metrics
Market Cap
$5.70B
Enterprise Value
$5.54B
P/E Ratio
-8.3x
PEG Ratio
0.9x
Price/Sales
9.9x
Growth & Margins
Revenue Growth (YoY)
-94.9%
Gross Margin
N/A
Operating Margin
-596.2%
Net Margin
-25.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.7%
Current Ratio
4.9x
Debt/Equity
137.2x
ROE
-37.1%
ROA
-6.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Arrowhead Pharmaceuticals Inc. (ARWR) Business Model
About Arrowhead Pharmaceuticals Inc.
What They Do
Develops innovative gene silencing medicines.
Business Model
Arrowhead Pharmaceuticals generates revenue by developing therapeutics using its proprietary RNA interference technology, focusing on diseases with limited treatment options. The company targets genetic causes of diseases, aiming to create effective and lasting solutions, which could lead to partnerships and licensing deals with larger pharmaceutical firms.
Additional Information
As a key player in the biotechnology sector, Arrowhead Pharmaceuticals is committed to advancing precision medicine and addressing unmet medical needs. Its focus on RNAi technology positions it at the forefront of medical innovation, with potential for significant impact on healthcare outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
609
CEO
Dr. Christopher R. Anzalone Ph.D.
Country
United States
IPO Year
1997
Website
arrowheadpharma.comArrowhead Pharmaceuticals Inc. (ARWR) Latest News & Analysis
Latest News
Quick Summary
A fund sold 138,263 shares of Arrowhead Pharmaceuticals for $3.04 million, reducing its stake to 473,951 shares valued at $16.35 million, now 2.94% of AUM.
Why It Matters
The sale of Arrowhead Pharmaceuticals shares reduces its significance in the fund, potentially signaling a shift in investment strategy or confidence in the company’s future.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present a study on Zodasiran for Homozygous Familial at the AHA Scientific Sessions 2025, scheduled for November 10, 2025, at 2:34 pm CST.
Why It Matters
Arrowhead Pharmaceuticals' upcoming presentation on Zodasiran could indicate future advancements in treatment, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its fiscal 2025 financial results.
Why It Matters
Arrowhead Pharmaceuticals' upcoming financial results call could signal key insights into its performance and future strategies, impacting stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18 days ago
Quick Summary
Arrowhead Pharmaceuticals approved inducement grants for 84 new employees, totaling 127,230 restricted stock units, outside of approved equity incentive plans.
Why It Matters
The grant of restricted stock units to new employees may enhance talent acquisition, potentially driving innovation and growth, which can positively impact Arrowhead Pharmaceuticals' stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
25 days ago
Quick Summary
Arrowhead Pharmaceuticals closed a global licensing agreement with Novartis, following regulatory clearance. The deal grants Novartis exclusive worldwide rights.
Why It Matters
The closing of Arrowhead Pharmaceuticals' collaboration with Novartis indicates potential revenue growth and validation of its technology, impacting stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted a request for regulatory approval to start a Phase 1/2a trial for ARO-DIMER-PA, an RNAi therapy targeting atherosclerotic cardiovascular disease.
Why It Matters
Arrowhead Pharmaceuticals' new trial for ARO-DIMER-PA could significantly impact its market position in cardiovascular treatments, potentially increasing investor interest and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ARWR Stock
What is Arrowhead Pharmaceuticals Inc.'s (ARWR) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Arrowhead Pharmaceuticals Inc. (ARWR) has a median price target of $45.00. The highest price target is $80.00 and the lowest is $17.00.
Is ARWR stock a good investment in 2026?
According to current analyst ratings, ARWR has 9 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARWR stock?
Wall Street analysts predict ARWR stock could reach $45.00 in the next 12 months. This represents a 9.1% increase from the current price of $41.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arrowhead Pharmaceuticals Inc.'s business model?
Arrowhead Pharmaceuticals generates revenue by developing therapeutics using its proprietary RNA interference technology, focusing on diseases with limited treatment options. The company targets genetic causes of diseases, aiming to create effective and lasting solutions, which could lead to partnerships and licensing deals with larger pharmaceutical firms.
What is the highest forecasted price for ARWR Arrowhead Pharmaceuticals Inc.?
The highest price target for ARWR is $80.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 93.9% increase from the current price of $41.26.
What is the lowest forecasted price for ARWR Arrowhead Pharmaceuticals Inc.?
The lowest price target for ARWR is $17.00 from Shawn Egan at Citigroup, which represents a -58.8% decrease from the current price of $41.26.
What is the overall ARWR consensus from analysts for Arrowhead Pharmaceuticals Inc.?
The overall analyst consensus for ARWR is bullish. Out of 22 Wall Street analysts, 9 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are ARWR stock price projections?
Stock price projections, including those for Arrowhead Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 16, 2025 2:49 AM UTC